Coronavirus Disease 2019 (COVID-19) is causing unprecedented disruptions to the U.S. economy. Government officials and health professionals are predicting that these disruptions could continue through September. Businesses are having to face the challenges of operating remotely; many are cancelling non-essential travel – hampering long-planned meetings and conventions. Global supply chains are impeded as countries work
Thomas G. Allen‡
Thomas G. Allen is a Shareholder in Greenberg Traurig’s International Arbitration and Litigation Group. His practice focuses on cross-border disputes in a variety of industries with an emphasis on energy, manufacturing, construction, and aviation. Thomas has wide-ranging experience in high-value international and U.S. arbitrations. He also litigates the enforceability of arbitration clauses and arbitration awards in U.S. Courts. Thomas is a frequent lecturer on international arbitration topics and is a former adjunct professor in the international arbitration discipline. He acts as an arbitrator and has advised foreign governments and corporations in investor-state dispute settlement matters. Thomas currently serves as Vice Chair of the Dispute Resolution and Arbitration Committee of the Inter-Pacific Bar Association. He also counsels foreign and U.S. corporations on U.S. government investigations and enforcement proceedings. Prior to joining Greenberg Traurig, Thomas was a partner at another Global 100 law firm.
‡ Admitted in the District of Columbia and Virginia. Has not taken the Chinese national PRC judicial qualification examination. Not admitted in Japan.
Coronavirus Disease 2019 and Force Majeure Contract Clauses
While it is too early to predict how long the Coronavirus Disease 2019 (COVID-19) will disrupt everyday life, it isn’t too soon to proactively consider your potential risk and understand both potential consequences and benefits of the legal landscape when planning for or dealing with the COVID-19 outbreak.
Read the full GT Alert, “Coronavirus…
Does Section 1782 Apply to Discovery in Private International Commercial Arbitration Proceedings?
Life sciences companies should pay attention to an ongoing action in Delaware that could have implications for whether they can obtain (or be subjected to) U.S. discovery in international arbitration under 28 U.S.C. § 1782. Section 1782 is a powerful tool that permits litigants to obtain broad discovery in the United States for use in…